Fiducial Markers Implanted during Prostate Brachytherapy for Guiding Conformal External Beam Radiation Therapy

Prostate movement imposes limits on safe dose-escalation with external beam radiation therapy. If the precise daily location of the prostate is known, dose escalation becomes more feasible. We have developed an approach to dose escalation using a combination of prostate brachytherapy followed by external beam radiation therapy in which fiducial markers are placed along with125 I seeds during transperineal interstitial permanent prostate brachytherapy. These markers serve to verify daily prostate location during the subsequent external beam radiotherapy. Prior to implementing this approach, preliminary studies were performed to test visibility of the markers. Three different125 I seed models, as well as gold and silver marker seeds were placed within tissue-equivalent phantoms. Images were obtained with conventional x-rays (75–85 kV) and 6 MV photons from a linear accelerator. All125 I seed models were clearly visible on conventional x-rays but none were seen with 6 MV photons. The gold markers were visible with both energies. The silver markers were visible with conventional x-rays and 6 MV x-rays, but not as clearly as the gold seeds at 6 MV. Subsequently, conventional x-rays, CT scans, and 6 MV port films were obtained in 29 patients in whom fiducial gold marker seeds were implanted into the prostate during125 I prostate brachytherapy. To address the possibility of “seed migration” within the prostate, CT scans were repeated 5 weeks apart in 14 patients and relative positions of the gold seeds were evaluated. The repeated CT scans showed no change in intraprostatic gold marker location, suggesting minimal migration. The gold seeds were visible with conventional x-rays, CT, and 6 MV port films in all patients. During the course of external beam radiation therapy, the gold markers were visible on routine 6 MV port films and were seen in different locations from film to film suggesting prostate motion. Mean daily displacement was 4–5 mm in the anterior-posterior, and 4–5 mm in superior-inferior dimensions. Left-right displacement appeared less, averaging 2–3 mm. We conclude that implantation of gold marker seeds during prostate brachytherapy represents an easily implemented and practical means of prostate localization during subsequent image-guided external beam radiotherapy. With such markers, conformality of the external beam component can be confidently improved without expensive new equipment.

[1]  T E Schultheiss,et al.  Survival advantage for prostate cancer patients treated with high-dose three-dimensional conformal radiotherapy. , 1999, The cancer journal from Scientific American.

[2]  L. Gras,et al.  Estimation of the incidence of late bladder and rectum complications after high-dose (70-78 GY) conformal radiotherapy for prostate cancer, using dose-volume histograms. , 1998, International journal of radiation oncology, biology, physics.

[3]  A. Pollack,et al.  External beam radiotherapy dose response of prostate cancer. , 1997, International journal of radiation oncology, biology, physics.

[4]  Michael G Herman,et al.  Technical aspects of daily online positioning of the prostate for three-dimensional conformal radiotherapy using an electronic portal imaging device. , 2003, International journal of radiation oncology, biology, physics.

[5]  W. H. Williams,et al.  Simultaneous radiotherapy for prostate cancer: 125I prostate implant followed by external-beam radiation. , 1998, The cancer journal from Scientific American.

[6]  J M Slater,et al.  Conformal proton therapy for early-stage prostate cancer. , 1999, Urology.

[7]  R. Pötter,et al.  The influence of a rectal balloon tube as internal immobilization device on variations of volumes and dose-volume histograms during treatment course of conformal radiotherapy for prostate cancer. , 2002, International journal of radiation oncology, biology, physics.

[8]  K. Wallner,et al.  103Pd brachytherapy and external beam irradiation for clinically localized, high-risk prostatic carcinoma. , 1996, International journal of radiation oncology, biology, physics.

[9]  K. C. Lee,et al.  Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-Gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma. , 1999, Cancer.

[10]  J. Manola,et al.  A practical method to achieve prostate gland immobilization and target verification for daily treatment. , 2001, International journal of radiation oncology, biology, physics.

[11]  T E Schultheiss,et al.  Daily CT localization for correcting portal errors in the treatment of prostate cancer. , 1998, International journal of radiation oncology, biology, physics.

[12]  William R. Fair,et al.  DOSE ESCALATION WITH THREE-DIMENSIONAL CONFORMAL RADIATION THERAPY AFFECTS THE OUTCOME IN PROSTATE CANCER , 1998 .

[13]  Jan J W Lagendijk,et al.  Clinical feasibility study for the use of implanted gold seeds in the prostate as reliable positioning markers during megavoltage irradiation. , 2003, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[14]  J. Crook,et al.  Prostate motion during standard radiotherapy as assessed by fiducial markers. , 1995, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[15]  T E Schultheiss,et al.  Ultrasound-based stereotactic guidance in prostate cancer--quantification of organ motion and set-up errors in external beam radiation therapy. , 2000, Computer aided surgery : official journal of the International Society for Computer Aided Surgery.

[16]  L. Dillehay,et al.  Sensitization processes in human tumor cells during protracted irradiation: possible exploitation in the clinic. , 1992, International journal of radiation oncology, biology, physics.

[17]  Shinichi Shimizu,et al.  Registration accuracy and possible migration of internal fiducial gold marker implanted in prostate and liver treated with real-time tumor-tracking radiation therapy (RTRT). , 2002, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[18]  C. Ling,et al.  Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. , 1999, International journal of radiation oncology, biology, physics.

[19]  P. Bergström,et al.  High-precision conformal radiotherapy (HPCRT) of prostate cancer--a new technique for exact positioning of the prostate at the time of treatment. , 1998, International journal of radiation oncology, biology, physics.

[20]  E. B. Butler,et al.  Intensity-modulated radiation therapy (IMRT) for prostate cancer with the use of a rectal balloon for prostate immobilization: acute toxicity and dose-volume analysis. , 2001, International journal of radiation oncology, biology, physics.

[21]  T E Schultheiss,et al.  A comparison of daily CT localization to a daily ultrasound-based system in prostate cancer. , 1999, International journal of radiation oncology, biology, physics.

[22]  G Starkschall,et al.  Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-Gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma. , 1999, Cancer.

[24]  Michael J. Zelefsky,et al.  High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. , 2002, International journal of radiation oncology, biology, physics.

[25]  Wilfred Sewchand,et al.  Marker seed migration in prostate localization. , 2002, International journal of radiation oncology, biology, physics.

[26]  Jean Pouliot,et al.  (Non)-migration of radiopaque markers used for on-line localization of the prostate with an electronic portal imaging device. , 2003, International journal of radiation oncology, biology, physics.

[27]  T R Willoughby,et al.  Short-course intensity-modulated radiotherapy for localized prostate cancer with daily transabdominal ultrasound localization of the prostate gland. , 2000, International journal of radiation oncology, biology, physics.

[28]  G K Svensson,et al.  Ultrasound image fusion for external beam radiotherapy for prostate cancer. , 1996, International journal of radiation oncology, biology, physics.

[29]  A. Markoe,et al.  Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406. , 2000, International journal of radiation oncology, biology, physics.

[30]  T Haycocks,et al.  Positioning errors and prostate motion during conformal prostate radiotherapy using on-line isocentre set-up verification and implanted prostate markers. , 2001, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[31]  J Pouliot,et al.  Electronic portal imaging device detection of radioopaque markers for the evaluation of prostate position during megavoltage irradiation: a clinical study. , 1997, International journal of radiation oncology, biology, physics.